TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
CONCLUSION: The plasma TERT mutation was detected in 44% of HCC patients and in none of non-HCC cirrhotic patients; and was associated with increased mortality. We propose the TERT C228T mutation in ctDNA as a promising HCC biomarker for prognosis.
PMID: 33103505 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Cancer & Oncology | Carcinoma | Denmark Health | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | PET Scan | Urology & Nephrology